Department of Emergency and Critical Care, Angell Animal Medical Center, Boston, Massachusetts, USA.
J Vet Emerg Crit Care (San Antonio). 2022 Nov;32(6):791-799. doi: 10.1111/vec.13237. Epub 2022 Sep 1.
To describe the signalment, dosing, adverse events, and patient diagnosis for dogs and cats admitted to the critical care unit (CCU) receiving tranexamic acid (TXA).
Case series from 2018 to 2019.
Private referral and primary care veterinary hospital.
Two hundred and sixty-six dogs and 28 cats.
None.
Records of dogs and cats admitted to the CCU that received TXA were evaluated. A diagnosis was assigned to each patient based on the International Statistical Classification of Diseases system. "Neoplasia" ([most frequently] hemangiosarcoma) (89/226 [39%]) and "diseases of the blood and blood forming organs" (idiopathic hemoabdomen, pericardial effusion) (78/226 [34%]) were the most common disease processes for which dogs received TXA. In cats, "diseases of the blood and blood forming organs" (idiopathic hemoabdomen) (9/28 [32%]), "neoplasia" (hemangiosarcoma, mast cell tumor, carcinoma) (7/28 [25%]), and "injury, poisoning, or certain other consequences of external causes" (high-rise syndrome) (5/28 [17%]) were most common. One hundred and forty-eight dogs (65%) and 13 cats (46%) underwent an invasive procedure during hospitalization. Thirty percent (70/226) of dogs received a packed RBC (pRBC) transfusion. Administration of TXA before or after pRBC transfusion did not significantly affect median dose of pRBC administered (P = 0.808). The median IV dose of TXA was similar for dogs and cats at 10 mg/kg. One cat received a 10 times overdose of TXA and did not suffer any appreciable adverse effects. Adverse events were reported in 1.7% (4/226) of dogs including hypersalivation (3/226) and seizure (1/226) in a dog that received a cumulative dose of 280 mg/kg of TXA. Hypersalivation was the only adverse event reported in 3% (1/28) of cats.
TXA is primarily utilized in critically ill dogs and cats diagnosed with neoplasia, bleeding disorders, and trauma at this institution. Adverse events were infrequent and largely mild.
描述在接受氨甲环酸（TXA）治疗的入住重症监护病房（CCU）的犬和猫的特征、剂量、不良反应和患者诊断。
2018 年至 2019 年的病例系列。
私人转诊和初级保健兽医医院。
266 只狗和 28 只猫。
无。
评估了入住 CCU 并接受 TXA 治疗的犬和猫的记录。根据国际疾病统计分类系统为每位患者分配了一个诊断。“肿瘤”（最常见的是血管肉瘤）（89/226 [39%]）和“血液和造血器官疾病”（特发性血腹、心包积液）（78/226 [34%]）是犬接受 TXA 的最常见疾病过程。在猫中，“血液和造血器官疾病”（特发性血腹）（9/28 [32%]）、“肿瘤”（血管肉瘤、肥大细胞瘤、癌）（7/28 [25%]）和“损伤、中毒和某些其他外部原因的后果”（高层综合征）（5/28 [17%]）最为常见。148 只狗（65%）和 13 只猫（46%）在住院期间进行了侵入性手术。30%（70/226）的狗接受了浓缩红细胞（pRBC）输血。在输血前或输血后给予 TXA 并不会显著影响输血的 pRBC 平均剂量（P=0.808）。狗和猫的 IV 剂量中位数相似，均为 10mg/kg。一只猫接受了 10 倍过量的 TXA，但没有遭受任何明显的不良反应。在 1.7%（4/226）的狗中报告了不良反应，包括 3 只狗出现过度流涎（3/226）和 1 只狗出现癫痫发作（1/226），这只狗接受了 280mg/kg 的 TXA 累积剂量。在 3%（1/28）的猫中，只有一只猫报告了过度流涎。
在该机构，TXA 主要用于诊断患有肿瘤、出血性疾病和创伤的重症监护病房的犬和猫。不良反应罕见且多为轻度。
